Press

• Beyond the direct impact of biotechnology on human health and the planet, investment in science and biotechnology has a direct relationship with the competitiveness, sustainability, and economic resilience of countries.
• Biotechnological innovations will determine the well-being of future generations, but for this to happen and for Spain to fully harness its potential, there needs to be a political and social will that provides the industry with measures and resources to ensure its full development.
• Spain needs a clear regulatory framework and support for the biotechnological industry with long-term investments, support that specifically addresses the needs of biotech companies, and measures to boost research talent.

• Ensuring food security and mitigating the impacts of climate change will not be possible without innovation in agriculture.
• Through food waste and the insect industry, proteins are being produced in a more sustainable manner.
• Biotechnology enables the transformation of certain types of waste into raw materials for industry, avoiding their disposal in landfills and reducing the footprint of processes and products.

• The President of the Generalitat de Catalunya, Pere Aragonès i Garcia, and the General Manager of Amgen and member of the Board of Directors of AseBio and the Board of Trustees of Biocat, Fina Lladós, officially close the fair.
•  Over 2,100 attendees and more than 220 exhibitors gathered over the course of the three-day congress.
• BIOSPAIN has evolved into a platform for fostering the next generation of startups, with over 5,000 one-to-one meetings and more than 30 startup presentations to investors.

• The sector has radically transformed the discovery of new drugs and therapeutic solutions.
• Worldwide, there are over 300 approved medications for approximately 250 indications and a thousand molecules in various stages of research.
• Biotechnological development is opening new horizons in the field of mental health.

• The majority of biotechnology companies are small and micro-enterprises that do not have products on the market and do not generate the necessary resources to finance their activities.
• There is an increasing alignment between specialized venture capital and emerging biotechnology companies.
• Strategic autonomy in the European healthcare sector can be supported in three areas: simplifying the European regulatory framework, reducing administrative burdens, and removing barriers to investment.

• The new edition of the international flagship event in the biotech sector will take place in Barcelona from September 26 to 28, in collaboration with Biocat, the Government of Catalonia, and the Barcelona City Council.
• The BIOSPAIN 2023 program consists of more than 60 sessions that will analyze areas such as health, planetary sustainability, Europe's strategic autonomy, and global threats like antibiotic resistance, among other topics.
• Within the framework of BIOSPAIN 2023, the "AseBio 2023 Journalism Awards" will be held. These awards highlight the excellent scientific journalism produced in Spain and will recognize journalists who give voice to the work of the Spanish biotechnology sector.

• The European project ShapingBio, created with the aim of better understanding and gaining knowledge of the innovation ecosystem in the European bioeconomy sector, will be present at BIOSPAIN.
• Under the title "Shaping Bioeconomy in Europe," the session offered by ShapingBio at BIOSPAIN 2023 will delve into the challenges and opportunities that require special attention and consideration for promoting the bioeconomy in Europe.

• During the Presidency of the Council of the European Union, Spain will lead the dialogue on these critical policies for European patients, food safety, and the green transition.
• "We need to find a path that ensures access for all patients to medications and reduces waiting times," says Ana Polanco, President of AseBio.
• "Europe needs to define a predictable regulatory framework for new genome editing techniques. Only then can we harness our scientific, human, infrastructure, and raw material strengths to build a competitive ecosystem in industrial biotechnology," explains Ion Arocena, CEO of AseBio.

Over 30 innovative biotech companies possess the comprehensive capabilities to develop advanced therapies, from initial R&D through manufacturing, efficient transfer and distribution